Eli Lilly and Company, Novo Nordisk, and Nxera Pharma are noted as key players in the alcohol use disorder market.

The entities involved

• Eli Lilly and Company →

  American pharmaceutical company

  • Trust plans to cut positions in Eli Lilly and Cardinal Health while seeking diversification from data-center exposure.06:04
  • Nvidia is a top holding in VOO, which also holds Apple Inc. as a major position. Warren Buffett advises investing in S&P 500 ETFs, noting Eli Lilly as a key non-tech giant.Wed 21:56
• Novo Nordisk →

  Danish pharmaceutical company

  • Denver hosts the annual MASH meeting, featuring presentations from Novo Nordisk and Gilead Sciences on new therapies.Thu 04:52
  • Novo Nordisk's repurchase program is operating under the regulations of the European Union.Tue 16:52
• Nxera Pharma →

  company in Tokyo, Japan

  • AbbVie and Nxera Pharma announced a collaboration to discover novel medicines.Wed 15:33
  • Nxera Pharma licensed a program to AbbVie.Wed 15:33

Related events

• Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Jun 18
• AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.Jun 8
• Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.Jun 8
• Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.Sep 23